AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Benjamin Edwards Inc.

Benjamin Edwards Inc. lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,075 shares of the company's stock after selling 3,796 shares during the period. Benjamin Edwards Inc.'s holdings in AstraZeneca were worth $3,674,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. World Investment Advisors LLC grew its holdings in shares of AstraZeneca by 115.5% during the third quarter. World Investment Advisors LLC now owns 8,267 shares of the company's stock worth $644,000 after buying an additional 4,430 shares in the last quarter. Tidal Investments LLC raised its holdings in AstraZeneca by 5.8% in the 3rd quarter. Tidal Investments LLC now owns 6,649 shares of the company's stock valued at $518,000 after acquiring an additional 362 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after purchasing an additional 707 shares during the period. Nordea Investment Management AB acquired a new stake in shares of AstraZeneca during the fourth quarter worth $754,000. Finally, Legacy Wealth Management LLC MS grew its position in shares of AstraZeneca by 27.3% in the fourth quarter. Legacy Wealth Management LLC MS now owns 3,948 shares of the company's stock valued at $259,000 after purchasing an additional 846 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.4 %

Shares of NASDAQ:AZN traded up $0.27 during mid-day trading on Friday, hitting $67.57. 6,215,921 shares of the company traded hands, compared to its average volume of 5,141,616. The firm has a market cap of $209.55 billion, a P/E ratio of 29.90, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The firm's 50 day simple moving average is $71.33 and its 200 day simple moving average is $69.70. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business's revenue was up 7.2% on a year-over-year basis. During the same period last year, the business earned $2.06 EPS. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

AZN has been the subject of a number of research analyst reports. Morgan Stanley assumed coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They set an "overweight" rating for the company. BNP Paribas assumed coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of "Buy" and an average target price of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.